Health News Archive - February 27, 2006
By Nita Bhalla PORT LOUIS (Reuters) - The number of people in Mauritius infected with a mosquito-borne disease which is ravaging through the Indian Ocean region has risen to 962 from 341 the previous week, the government said.
Restrictions on abortion that would be the most severe since the U.S. Supreme Court legalized the practice 33 years ago are likely to turn South Dakota into an expensive legal battleground should they become law.
With billions of dollars pouring in to fight Africa's HIV/AIDS epidemic, Tanzanian AIDS counsellor Gandencia Bazil has a simple request.
France began vaccinating more than 300,000 geese and ducks against avian flu on Monday while Niger became the second West African country to be hit by a virus which is spreading among birds at unprecedented speed.
LONDON (Reuters) - A re-usable, lightweight suit could help save the lives of thousands of women in poor countries who die each year during childbirth, researchers said on Monday.
NEW YORK (Reuters Health) - A series of therapy sessions designed to address all aspects of cancer patients' lives, from physical fitness to spiritual well-being, can help maintain their quality of life and even improve it, a new study shows.
By Philip Pullella VATICAN CITY (Reuters) - Pope Benedict on Monday reaffirmed Catholic teaching that life begins at the moment of conception, saying embryos are "sacred and inviolable" even before they become implanted in a mother's uterus.
By DONNA REDMAN For the Journal There shouldn't be any excuses for someone to get bored in Rio Rancho. With plenty of open space, good weather and some creative planning, there's already a wealth of things to do. Start with activities offered by the city. "(As of Nov.
Prostate cancer recurrence after surgery to remove the prostate is not only influenced by features of the tumor but also by the skill or level of experience of the surgeon, according to a study presented at a medical conference in California.
NEW YORK (Reuters Health) - The COX-2 inhibitor Celebrex (celecoxib) causes fewer gastrointestinal complications than traditional nonsteroidal anti-inflammatory painkillers or NSAIDs, without raising the risk of cardiovascular events, according to results of a large, prospective, 3-month trial.